Роль вітаміну D у розвитку, перебігу та лікуванні артеріальної гіпертензії

В. Є. Кондратюк; А. П. Тарасюк

doi:10.30978/CEES-2022-4-61

Автор(и)

В. Є. Кондратюк Національний медичний університет імені О. О. Богомольця, Київ, Ukraine http://orcid.org/0000-0002-4891-2338
А. П. Тарасюк Національний медичний університет імені О. О. Богомольця, Київ, Ukraine http://orcid.org/0000-0003-0079-232X

DOI:

https://doi.org/10.30978/CEES-2022-4-61

Ключові слова:

вітамін D, артеріальна гіпертензія, паратгормон, ренін, ангіотензин ІІ

Анотація

The literature review considers the new universal molecule empagliflozin, which managed to change the glucose‑centric approach in endocrinology to an organoprotective one. The results of the pivotal clinical trials conducted with empagliflozin (EMPA‑REG‑OUTCOME, EMPEROR‑REDUCED, EMPEROR‑PRESERVED and EMPULSE) strongly support the ability of empagliflozin to reduce rates of cardiovascular death or hospitalization for heart failure and to slow down the progression of chronic kidney disease. Among the confirmed and potentially favorable metabolic consequences of empagliflozin administration, the following should be emphasized: a selective antihyperglycemic effect only in conditions of hyperglycemia/glucosuria, which does not depend either on insulin production or sensitivity of peripheral tissues to insulin but is limited only by the glomerular filtration rate. This effect allows avoiding hypoglycemia even in patients without diabetes. The drug is one of the most durable among oral hypoglycemic agents and allows to maintain the achieved HbA1c values for 6 — 8 years, delaying the initiation of insulin therapy in patients with type 2 diabetes mellitus. Empagliflozin was superior to placebo in preventing death from cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus. This effect resulted from the significant reduction in the risk of cardiovascular mortality without significant changes in nonfatal myocardial infarction or nonfatal stroke. Combination with other oral and injectable hypoglycemic drugs is possible. In case of combination with sulfonylurea drugs or insulin, the dose of the latter needs to be adjusted in the direction of its decrease. Weight loss of up to 2 — 3 kg against the background of empagliflozin is an expected phenomenon that can modify blood pressure indicators and insulin resistance. Empagliflozin has the ability to reduce steatosis and improve liver fibrosis scores in patients with NAFLD without type 2 diabetes mellitus.

Біографії авторів

В. Є. Кондратюк, Національний медичний університет імені О. О. Богомольця, Київ

д. мед. н., проф., зав. кафедри пропедевтики внутрішньої медицини № 2

А. П. Тарасюк, Національний медичний університет імені О. О. Богомольця, Київ

аспірант кафедри пропедевтики внутрішньої медицини № 2

Посилання

Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Washington (DC): National Academies Press (US); 2011.

Bouillon R, Carmeliet G, Lieben L, et al. Vitamin D and energy homeostasis: of mice and men. Nat Rev Endocrinol. 2014 Feb;10(2):79-87. doi: 10.1038/nrendo.2013.226.

Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr. 2016 Apr;103(4):1033-44. doi: 10.3945/ajcn.115.120873.

Martucci G, Tuzzolino F, Arcadipane A, et al. The effect of high-dose cholecalciferol on bioavailable vitamin D levels in critically ill patients: a post hoc analysis of the VITdAL-ICU trial. Intensive Care Med. 2017 Nov;43(11):1732-4. doi: 10.1007/s00134-017-4846-5.

Schleicher RL, Sternberg MR, Looker AC, et al. National Estimates of Serum Total 25-Hydroxyvitamin D and Metabolite Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry in the US Population during 2007-2010. J Nutr. 2016 May;146(5):1051-61. doi: 10.3945/jn.115.227728.

Sarafin K, Durazo-Arvizu R, Tian L, et al. Standardizing 25-hydroxyvitamin D values from the Canadian Health Measures Survey. Am J Clin Nutr. 2015 Nov;102(5):1044-50. doi: 10.3945/ajcn.114.103689.

Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr. 2016 Apr;103(4):1033-44. doi: 10.3945/ajcn.115.120873.

Cashman KD. Vitamin D deficiency: defining, prevalence, causes, and strategies of addressing. Calcif Tissue Int. 2020 Jan;106(1):14-29. doi: 10.1007/s00223-019-00559-4.

Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-57. doi: 10.1161/HYPERTENSIONAHA.120.15026.

Virani SS, Alonso A, Benjamin EJ, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757.

Oori MJ, Mohammadi F, Norouzi K, Fallahi-Khoshknab M, Ebadi A. Conceptual model of medication adherence in older adults with high blood pressure-an integrative review of the literature. Curr Hypertens Rev. 2019;15(2):85-92. doi: 10.2174/1573402114666181022152313.

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020 Apr;16(4):223-37. doi: 10.1038/s41581-019-0244-2.

Mehta V, Agarwal S. Does vitamin D deficiency lead to hypertension? Cureus. 2017 Feb 17;9(2):e1038. doi: 10.7759/cureus.1038.

DeLuca HF. Vitamin D: the vitamin and the hormone. Fed Proc. 1974 Nov;33(11):2211-9.

Bikle DD. Vitamin D: newer concepts of its metabolism and function at the basic and clinical level. J Endocr Soc. 2020 Feb 8;4(2):bvz038. doi: 10.1210/jendso/bvz038.

Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28. doi: 10.1152/ajprenal.00336.2004.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385.

Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007 Jun 11;167(11):1159-65. doi: 10.1001/archinte.167.11.1159.

Malik S, Fu L, Juras DJ, et al. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit Rev Clin Lab Sci. 2013 Jan-Feb;50(1):1-22. doi: 10.3109/10408363.2012.750262.

Clark A, Mach N. Role of vitamin D in the hygiene hypothesis: the interplay between vitamin D, vitamin D receptors, gut microbiota, and immune response. Front Immunol. 2016 Dec 23;7:627. doi: 10.3389/fimmu.2016.00627.

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002 Jul;110(2):229-38. doi: 10.1172/JCI15219.

Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007 Oct 12;282(41):29821-30. doi: 10.1074/jbc.M705495200.

Kong J, Qiao G, Zhang Z, Liu SQ, Li YC. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008 Dec;74(12):1577-81. doi: 10.1038/ki.2008.452.

Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E125-32. doi: 10.1152/ajpendo.00224.2004.

Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998 Aug 25;98(8):800-7. doi: 10.1161/01.cir.98.8.800.

Szeto FL, Reardon CA, Yoon D, et al. Vitamin D receptor signaling inhibits atherosclerosis in mice. Mol Endocrinol. 2012 Jul;26(7):1091-101. doi: 10.1210/me.2011-1329.

Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003 Aug;14(6):274-81. doi: 10.1016/s1043-2760(03)00111-5.

Shi Y, Liu T, Yao L, et al. Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. Sci Rep. 2017 Jun 12;7(1):3312. doi: 10.1038/s41598-017-03474-6.

Cheng Q, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia. 2011 Aug;54(8):2077-81. doi: 10.1007/s00125-011-2100-1.

Lotito A, Teramoto M, Cheung M, Becker K, Sukumar D. Serum parathyroid hormone responses to vitamin D supplementation in overweight/obese adults: A systematic review and meta-analysis of randomized clinical trials. Nutrients. 2017 Mar 6;9(3):241. doi: 10.3390/nu9030241.

Vaidya A, Williams JS. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism. 2012 Apr;61(4):450-8. doi: 10.1016/j.metabol.2011.09.007.

Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007 Jun 11;167(11):1159-65. doi: 10.1001/archinte.167.11.1159.

Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007 Jul;20(7):713-9. doi: 10.1016/j.amjhyper.2007.01.017.

Ke L, Mason RS, Kariuki M, Mpofu E, Brock KE. Vitamin D status and hypertension: a review. Integr Blood Press Control. 2015 Apr 8;8:13-35. doi: 10.2147/IBPC.S49958.

Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol. 2013 Mar;28(3):205-21. doi: 10.1007/s10654-013-9790-2.

Pilz S, Gaksch M, Kienreich K, et al. Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension. 2015 Jun;65(6):1195-201. doi: 10.1161/HYPERTENSIONAHA.115.05319.

Arora P, Song Y, Dusek J, et al. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015 Jan 20;131(3):254-62. doi: 10.1161/CIRCULATIONAHA.114.011732.

Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens. 2012 Nov;25(11):1215-22. doi: 10.1038/ajh.2012.111.

McGreevy C, Barry M, Davenport C, et al. The effect of vitamin D supplementation on arterial stiffness in an elderly community-based population. J Am Soc Hypertens. 2015 Mar;9(3):176-83. doi: 10.1016/j.jash.2014.12.019.

Witham MD, Ireland S, Houston JG, et al. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension. 2014 Apr;63(4):706-12. doi: 10.1161/HYPERTENSIONAHA.113.02177.

Chen WR, Liu ZY, Shi Y, et al. Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial. Atherosclerosis. 2014 Jul;235(1):102-9. doi: 10.1016/j.atherosclerosis.2014.04.011.

Mozaffari-Khosravi H, Loloei S, Mirjalili MR, Barzegar K. The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: a randomized, double-blind, placebo-controlled trial. Blood Press Monit. 2015 Apr;20(2):83-91. doi: 10.1097/MBP.0000000000000091.

Goel RK, Lal H. Role of vitamin d supplementation in hypertension. Indian J Clin Biochem. 2011 Jan;26(1):88-90. doi: 10.1007/s12291-010-0092-0.

Toxqui L, Blanco-Rojo R, Wright I, Pérez-Granados AM, Vaquero MP. Changes in blood pressure and lipid levels in young women consuming a vitamin D-fortified skimmed milk: a randomised controlled trial. Nutrients. 2013 Dec 5;5(12):4966-77. doi: 10.3390/nu5124966.

Legarth C, Grimm D, Wehland M, Bauer J, Krüger M. The impact of vitamin D in the treatment of essential hypertension. Int J Mol Sci. 2018 Feb 3;19(2):455. doi: 10.3390/ijms19020455.

He S, Hao X. The effect of vitamin D3 on blood pressure in people with vitamin D deficiency: A system review and meta-analysis. Medicine (Baltimore). 2019 May;98(19):e15284. doi: 10.1097/MD.0000000000015284.

Adamczak M, Surma S, Więcek A. Vitamin D and Arterial Hypertension: Facts and Myths. Curr Hypertens Rep. 2020 Jul 15;22(8):57. doi: 10.1007/s11906-020-01059-9. PMID: 32671631.

Sheikh V, Mozaianimonfared A, Gharakhani M, Poorolajal J, Ph D. Effect of vitamin D supplementation versus placebo on essential hypertension in patients with vitamin D deficiency: a double-blind randomized clinical trial. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1867-73. doi: 10.1111/jch.13926.

Mokhtari E, Hajhashemy Z, Saneei P. Serum vitamin D levels in relation to hypertension and pre-hypertension in adults: A systematic review and dose-response meta-analysis of epidemiologic studies. Front Nutr. 2022 Mar 10;9:829307. doi: 10.3389/fnut.2022.829307.